Unpacking Health Catalyst's Latest 10-K: A Deep Dive for Investors

Health Catalyst, Inc. (HCAT) recently filed its annual 10-K report, offering crucial insights into its performance, strategy, and financial health. This summary distills complex financial information into clear, actionable insights, helping investors understand the company's trajectory.

1. Business Overview & Performance Highlights

Health Catalyst (HCAT) empowers healthcare organizations to improve patient care and operational efficiency through its data analytics and technology solutions. The company generates revenue primarily from two segments: Technology (software and platforms) and Professional Services (consulting and support).

Financial Highlights (2025 vs. 2024):

• Total Revenue: Health Catalyst grew total revenue by 7.1% to $300 million in 2025, up from $280 million in 2024.
• Technology Revenue: This segment saw a 5.9% increase, reaching $180 million in 2025 ($170 million in 2024). Notably, recurring technology revenue—stable, subscription-based income—grew from $160 million in 2024 to $170 million in 2025, representing approximately 94.4% of total technology revenue for the year.
• Professional Services Revenue: The company's professional services revenue increased by 9.1%, climbing to $120 million in 2025 from $110 million in 2024.

2. Strategic Initiatives: Acquisitions & Restructuring

Growth Through Acquisitions: Health Catalyst aggressively pursued growth through acquisitions:

• In 2024, the company acquired Carevive Systems Inc. (May), Lumeon Ltd. (August), and Intraprise Health LLC. (November).
• This trend continued into 2025 with the acquisition of Upfront Healthcare Services in January.

These acquisitions aim to expand Health Catalyst's technology offerings, customer base, and market reach within the healthcare sector.

Operational Streamlining & Restructuring: The company initiated multiple restructuring plans, signaling a focus on internal changes:

• A 2023 plan resulted in $6 million in severance costs during 2024.
• Two additional plans, launched in January and August 2025, project $2.5 million in severance costs for 2025.

These efforts suggest Health Catalyst is prioritizing operational efficiency and workforce optimization, though they also represent ongoing costs and potential short-term disruption.

3. Financial Health (Debt, Cash, Liquidity)

Cash Position: Health Catalyst's liquid assets experienced a significant decline. Cash, cash equivalents, and short-term investments dropped 50%, from $80 million at the end of 2024 to $40 million by the end of 2025. This reduction raises concerns, especially given upcoming debt obligations.

Debt Obligations: A critical financial hurdle for the company is the $172.5 million in convertible notes maturing in April 2025. To address this and provide financial flexibility, Health Catalyst secured a new credit agreement in July 2024. This facility includes a $150 million term loan and a $100 million "delayed draw" term loan, which the company can access later if needed.

Overall Liquidity: The combination of decreasing cash reserves and substantial short-term debt indicates a tightened liquidity position. Managing the convertible notes is a top priority for Health Catalyst.

4. Key Risks to Consider

Investors should consider several key risks facing Health Catalyst:

• Debt Repayment: The $172.5 million in convertible notes due in April 2025 poses a significant short-term financial risk. The company's ability to repay, refinance, or convert these notes will heavily influence investor confidence.
• Decreasing Cash Reserves: The 50% reduction in cash and investments raises concerns about Health Catalyst's ability to fund operations, future acquisitions, or unexpected expenses without further financing.
• Acquisition Integration: Successfully integrating four acquired companies within a short period is complex. Failure to achieve expected synergies or operational efficiencies from these integrations could negatively impact financial performance and growth.
• Operational Disruption: While aimed at efficiency, multiple restructuring plans can disrupt operations, affect employee morale, and incur ongoing costs, potentially impacting productivity.

5. Management's Strategic Direction

Strategic Focus: Health Catalyst's strategy clearly centers on aggressive growth through acquisitions to expand its market footprint and product offerings. The company also strongly emphasizes operational efficiency through ongoing restructuring efforts.

Capital Allocation: While an authorized share repurchase plan of up to $75 million (approved August 2022) remains in place, Health Catalyst did not repurchase any shares in 2025. This indicates management's prioritization of capital for growth initiatives (acquisitions) and debt management over returning capital to shareholders via buybacks in the recent period.

6. Future Outlook

Management's Outlook & Guidance: Management's strategic direction indicates a commitment to continued revenue growth through strategic acquisitions and a focus on operational efficiency via restructuring.

---

Investor Takeaway:

Health Catalyst shows solid revenue growth, driven by both its technology and professional services segments, with a strong recurring revenue base. The company is actively expanding its market presence through strategic acquisitions and focusing on operational efficiency through restructuring. However, investors should closely monitor the company's liquidity position, particularly the significant decline in cash reserves and the upcoming maturity of $172.5 million in convertible notes. The success of integrating recent acquisitions and managing debt obligations will be crucial for Health Catalyst's near-term financial stability and long-term growth trajectory.